All measures distinguished the dementia and control groups and all markers associated with the cognitive test scores. 4 key findings →
Participants: 84 Evidence: low
Full summary, score breakdown and related studies → Original source
33,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
All measures distinguished the dementia and control groups and all markers associated with the cognitive test scores. 4 key findings →
Participants: 84 Evidence: low
Full summary, score breakdown and related studies → Original source
Semantic dementia is a syndrome of progressive deterioration in semantic memory (knowledge of objects, people, concepts and words). 1 key finding →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source
The difficulty in differentiating progressive supranuclear palsy (PSP, also called Steele-Richardson-Olszewski syndrome) from other related disorders was the incentive for a study to determine the clinical features that best distinguish PSP. 5 key findings →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
Recent theories have suggested that chronic pain could be partly maintained by maladaptive physiological responses of the organism facing a recurrent stressor. 5 key findings →
Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid imaging studies of presymptomatic familial Alzheimer's disease have revealed the striatum and thalamus to be the earliest sites of amyloid deposition. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our recently published data on children investigated within 5 days of a PFC showed that children investigated by MRI within 48 h of a PFC had large hippocampal volumes and prolongation of T2 relaxation time. 5 key findings →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source
Experimental studies indicate that overactivation of the DNA repair protein poly(ADP-ribose) polymerase (PARP) in response to oxidative damage to DNA can cause cell death due to depletion of NAD+. 3 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
It is currently unclear how amyloid-β and tau deposition are linked to changes in synaptic function and axonal structure over the course of Alzheimer's disease. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In contrast, all Alzheimer's disease variants showed diffuse patterns of (11)C-labelled Pittsburgh compound B binding, with posterior cortical atrophy additionally showing elevated uptake in occipital cortex compared with early-onset Alzheimer's disease. 4 key findings →
Participants: 17 Evidence: low
Full summary, score breakdown and related studies → Original source
Patients with early age-of-onset Alzheimer's disease show more rapid progression, more generalized cognitive deficits and greater cortical atrophy and hypometabolism compared to late-onset patients at a similar disease stage. 5 key findings →
Participants: 21 Evidence: low
Full summary, score breakdown and related studies → Original source
There have been 87 cases of superficial siderosis of the CNS reported in the world literature and 63 cases had developed the clinical syndrome with sufficient details to be reviewed. 1 key finding →
Participants: 22 Evidence: low
Full summary, score breakdown and related studies → Original source
Multiple avenues of research including epidemiology, molecular genetics and cell biology have identified links between Parkinson's disease and type 2 diabetes mellitus. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
The association between hearing impairment and dementia has emerged as a major public health challenge, with significant opportunities for earlier diagnosis, treatment and prevention. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease is a complex neurodegenerative disorder leading to a decline in cognitive function and mental health. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease research has largely concentrated on the study of cognitive decline, but the associated behavioural and neuropsychiatric symptoms are of equal importance in the clinical profile of the disease. 4 key findings →
Participants: 31 Evidence: low
Full summary, score breakdown and related studies → Original source
Confrontation naming is impaired in neurodegenerative conditions like Alzheimer's disease (AD), frontotemporal dementia (FTD) and corticobasal degeneration (CBD). 3 key findings →
Participants: 50 Evidence: low
Full summary, score breakdown and related studies → Original source
Conductance to outflow of CSF was measured in a prospective study of 80 patients with normal pressure hydrocephalus. 3 key findings →
Participants: 80 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease CSF biomarkers 42 amino acid long amyloid-β peptide (Aβ1-42), total tau protein (T-tau), and tau protein phosphorylated at threonine 181 (P-tau181) are considered surrogate biomarkers of Alzheimer's disease pathology, and significantly improve diagnostic accuracy. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Recent studies suggest that subcortical structures, including striatum, are vulnerable to amyloid-β accumulation and other neuropathological features in familial Alzheimer's disease due to autosomal dominant mutations. 5 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
It is well established that there are sex differences in response to Alzheimer's disease pathology, and growing evidence suggests that genetic factors may contribute to these differences. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent studies in cognitively unimpaired elderly individuals suggest that the APOE ε4 allele exerts a dosage-dependent effect on brain tau deposition. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Although previous studies demonstrated decreased functional connectivity in the default mode network in the cognitively normal older adults with amyloid burden, effects of amyloid burden in the other large-scale intrinsic connectivity networks are not yet clear. 4 key findings →
Participants: 27 Evidence: low
Full summary, score breakdown and related studies → Original source
Younger patients showed more severe impairment on visuo-spatial function, attention and executive function composite scores (P<0.05), while we found a trend towards poorer memory performance for older patients (P=0.11). 3 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source
The binding properties of the amyloid tracers FDDNP, AV-45, AV-1 and BF-227 were also compared with those of (3)H-Pittsburgh compound B in the frontal cortices of patients with Alzheimer's disease. 3 key findings →
Participants: 23 Evidence: low
Full summary, score breakdown and related studies → Original source
Nearly all adults with Down syndrome show neuropathology of Alzheimer's disease, including amyloid-β deposition, by their fifth decade of life. 4 key findings →
Participants: 63 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 33,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 33,780 records, built mostly from automated pulls of Europe PMC (68% of the library) and OpenAlex (15.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.1% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated